STAGE III RECTAL CANCER AJCC V8
Clinical trials for STAGE III RECTAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RECTAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RECTAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink rectal tumors with fewer side effects
Disease control OngoingThis early-stage study tests the safety of combining the chemotherapy drug TAS-102 with standard radiation for people with stage II or III rectal cancer that hasn't spread. The goal is to find the best dose that kills tumor cells while limiting side effects, before surgery to rem…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 16, 2026 08:03 UTC
-
New chemo cocktail may help rectal cancer patients skip surgery
Disease control OngoingThis study tests whether a three-drug chemotherapy combination (FOLFIRINOX) works better than standard two-drug combinations (FOLFOX or CAPOX) after radiation for stage II-III rectal cancer. The goal is to see if more patients can achieve a complete response, potentially avoiding…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Immunotherapy-Radiation combo shows promise against rectal cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can shrink advanced rectal tumors before surgery. About 31 adults with stage II or III rectal cancer that has a specific genetic feature (MSI-H/dMMR) will rec…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope: tailored therapy fights anal cancer in HIV patients
Disease control OngoingThis study tests a personalized approach for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab to help prevent the cancer from coming back. The goal is to see if …
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors or slow cancer growth in people with advanced colorectal cancer that no longer responds to cetuximab alone. About 46 adults with metastatic or inoperabl…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Immunotherapy boost may tame tough colorectal cancer
Disease control OngoingThis study is for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E) and has not responded to prior treatment. It compares the usual two-drug therapy (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC